Method of treating depression with delta receptor agonist compounds
AssigneeArdent Pharmaceuticals, Inc.
InventorsKwen-Jen Chang, William Pendergast, Peter J. Gengo
Life of this patent
Estimating the term…
Abstract
Compositions and methods for treatment of depression or other affective mood disorders or pathological mental and/or emotional states, by administration to a subject suffering or susceptible to same, of therapeutically effective delta receptor agonist compound(s), optionally in combination with other mood disorder-combating agents.
Claims47
A method of combating a mood disorder in a subject experiencing or susceptible to same, comprising administering to said subject an effective amount of a therapeutic composition comprising at least one compound selected from the group consisting of:
- 48 49 50 51 52 53
- where G═O-alkyl, N(alkyl)2, and any other pharmaceutically acceptable esters thereof;
- and pharmaceutically acceptable salts and esters thereof.
A composition for combating a mood disorder in a subject experiencing or susceptible to same, comprising at least one compound selected from the group consisting of:
- 54 55 56 57 58 59
- where G═O-alkyl, N(alkyl)2, and any other pharmaceutically acceptable esters thereof;
- and pharmaceutically acceptable salts and esters thereof.
A dose form comprising a patch affixable to a corporeal locus, and containing a composition for combating a mood disorder in a subject experiencing or susceptible to same, comprising at least one compound selected from the group consisting of:
- 60 61 62 63 64 65
- where G═O-alkyl, N(alkyl)2, and any other pharmaceutically acceptable esters thereof,
- and pharmaceutically acceptable salts and esters thereof.
A method of combating a mood disorder in a subject experiencing or susceptible to same, comprising administering to said subject an effective amount of a therapeutic composition comprising a diarylmethylpiperazine compound of the general formula:
- 66
- wherein:
- Ar1 is a 5- or 6-member carbocyclic or heterocyclic aromatic ring with atoms selected from the group consisting of carbon, nitrogen, oxygen and sulfur, and having on a first carbon atom thereof a substituent Y and on a second ring carbon thereof a substituent R1,
- Y is selected from the group consisting of:
- hydrogen;
- halogen;
- C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl;
- C1-C6 haloalkyl;
- C1-C6 alkoxy;
- C3-C6 cycloalkoxy;
- sulfides of the formula SR8 where R8 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, arylalkyl having a C5-C10 aryl moiety and an C1-C6 alkyl moiety, or C5-C10 aryl;
- sulfoxides of the formula SOR8 where R8 is the same as above;
- sulfones of the formula SO2R8 where R8 is the same as above;
- nitrile;
- C1-C6 acyl;
- alkoxycarbonylamino (carbamoyl) of the formula NHCO2R8 where R8 is the same as above;
- carboxylic acid, or an ester, amide, or salt thereof;
- aminomethyl of the formula CH2NR9R10 where R9 and R10 may be the same or different, and may be hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C2-C6 hydroxyalkyl, C2-C6 methoxyalkyl, C3-C6 cycloalkyl, or C5-C10 aryl, or R9 and R10 together may form a ring of 5 or 6 atoms, the ring atoms selected from the group consisting of N and C;
- carboxamides of the formula CONR9R10 where R9 and R10 are the same as above, or C2-C30 peptide conjugates thereof;
- and
- sulfonamides of the formula SO2NR9R10 where R9 and R10 are the same as above;
- R1 is hydrogen, halogen, or C1-C4 alkyl, C2-C4 alkenyl, C1-C4 alkynyl;
- Z is selected from the group consisting of hydrogen, hydroxyl, halogen and alkoxy;
- Ar2 is a 5 or 6-member carbocyclic or heterocyclic aromatic ring with atoms selected from the group consisting of carbon, nitrogen, oxygen and sulfur, and having on a carbon atom thereof a substituent X
- X is selected from the group consisting of hydrogen, halogen (fluorine, bromine, chlorine, iodine), hydroxy and alkoxy;
- or a pharmaceutically acceptable ester or salt thereof.
A therapeutic composition for combating a mood disorder in a subject experiencing or susceptible to same, comprising one or more diarylmethylpiperazine compounds of the general formula:
- 67
- wherein:
- Ar1 is a 5- or 6-member carbocyclic or heterocyclic aromatic ring with atoms selected from the group consisting of carbon, nitrogen, oxygen and sulfur, and having on a first carbon atom thereof a substituent Y and on a second ring carbon thereof a substituent R1,
- Y is selected from the group consisting of:
- hydrogen;
- halogen;
- C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl;
- C1-C6 haloalkyl;
- C1-C6 alkoxy;
- C3-C6 cycloalkoxy;
- sulfides of the formula SR8 where R8 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, arylalkyl having a C5-C10 aryl moiety and an C1-C6 alkyl moiety, or C5-C10 aryl;
- sulfoxides of the formula SOR8 where R8 is the same as above;
- sulfones of the formula SO2R8 where R8 is the same as above;
- nitrile;
- C1-C6 acyl;
- alkoxycarbonylamino (carbamoyl) of the formula NHCO2R8 where R8 is the same as above;
- carboxylic acid, or an ester, amide, or salt thereof;
- aminomethyl of the formula CH2NR9R10 where R9 and R10 may be the same or different, and may be hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C2-C6 hydroxyalkyl, C2-C6 methoxyalkyl, C3-C6 cycloalkyl, or C5-C10 aryl, or R9 and R10 together may form a ring of 5 or 6 atoms, the ring atoms selected from the group consisting of N and C;
- carboxamides of the formula CONR9R10 where R9 and R10 are the same as above, or C2-C30 peptide conjugates thereof;
- and
- sulfonamides of the formula SO2NR9R10 where R9 and R10 are the same as above;
- R1 is hydrogen, halogen, or C1-C4 alkyl, C2-C4 alkenyl, C1-C4 alkynyl;
- Z is selected from the group consisting of hydrogen, hydroxyl, halogen and alkoxy;
- Ar2 is a 5 or 6-member carbocyclic or heterocyclic aromatic ring with atoms selected from the group consisting of carbon, nitrogen, oxygen and sulfur, and having on a carbon atom thereof a substituent X
- X is selected from the group consisting of hydrogen, halogen (fluorine, bromine, chlorine, iodine), hydroxy and alkoxy;
- or a pharmaceutically acceptable ester or salt thereof.
A composition for combating a mood disorder in a subject experiencing or susceptible to same, comprising a diarylmethylpiperazine compound of the general formula:
- 68
- wherein:
- Ar1 is 6-member carbocyclic aromatic ring having on a carbon atom thereof a substituent Y, wherein Y is a carboxamide of the formula CONR9R10 where R9 and R10 are both an ethyl group;
- Z is selected from the group consisting of hydrogen, hydroxyl, and alkoxy;
- and
- Ar2 is a 6-member carbocyclic aromatic ring having on a carbon atom thereof a substituent X and wherein X is a halogen,
- or a pharmaceutically acceptable ester or salt thereof.
A method of combating a mood disorder in a subject experiencing or susceptible to same, comprising administering to said subject an effective amount of a therapeutic composition comprising a diarylmethylpiperazine compound of the general formula:
- 69
- wherein:
- Ar1 is 6-member carbocyclic aromatic ring having on a carbon atom thereof a substituent Y, wherein Y is a carboxamide of the formula CONR9R10 where R9 and R10 are both an ethyl group;
- Z is selected from the group consisting of hydrogen, hydroxyl, and alkoxy;
- and
- Ar2 is a 6-member carbocyclic aromatic ring having on a carbon atom thereof a substituent X and wherein X is a halogen,
- or a pharmaceutically acceptable ester or salt thereof.
A therapeutic composition for combating a mood disorder in a subject experiencing or susceptible to same, comprising a diarylmethylpiperazine compound of the formula:
- 70
- or a pharmaceutically acceptable ester or salt thereof.
A therapeutic composition for combating a mood disorder in a subject experiencing or susceptible to same, comprising a diarylmethylpiperazine compound of the formula:
- 71
- or a pharmaceutically acceptable ester or salt thereof.
A therapeutic composition for combating a mood disorder in a subject experiencing or susceptible to same, comprising a diarylmethylpiperazine compound of the formula:
- 72
- or a pharmaceutically acceptable ester or salt thereof.
A therapeutic composition for combating a mood disorder in a subject experiencing or susceptible to same, comprising a diarylmethylpiperazine compound of the formula:
- 73
- or a pharmaceutically acceptable ester or salt thereof.
A therapeutic composition for combating a mood disorder in a subject experiencing or susceptible to same, comprising a diarylmethylpiperazine compound of the formula:
- 74
- or a pharmaceutically acceptable ester or salt thereof.
Dependencies are inferred from the claim text.